Paladin - For Investors

BUSINESS DEVELOPMENT

	Menu
	Financial Statements Financial Reports Securities Filing Investor Resources Fact Sheet Presentations Analyst Coverage Calendar of Events FAQ Shareholder Services Investor Kit Investor Information News Press Releases Corporate News Awards

PRESS RELEASES

COMMUNIQUÉS DE PRESSE (Français)

2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |

December 12, 2011
PALADIN LABS ANNOUNCES THE CANADIAN LAUNCH OF DIGIFAB(TM) DIGOXIN IMMUNE FAB (OVINE)
(Also in PDF format)

November 28, 2011
PALADIN ANNOUNCES AGREEMENT FOR NOVEL OTC PRODUCT TO PREVENT TRAVELLERS' DIARRHEA
(Also in PDF format)

November 3, 2011
PALADIN REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS ACHIEVES RECORD QUARTERLY REVENUES
(Also in PDF format)

October 27, 2011
NOTICE OF PALADIN LABS' THIRD QUARTER 2011 RESULTS CONFERENCE CALL
(Also in PDF format)

October 7, 2011
PALADIN LABS COMPLETES ACQUISITION OF LABOPHARM
(Also in PDF format)

October 5, 2011
LABOPHARM INC. SHAREHOLDERS VOTE TO APPROVE ACQUISITION BY PALADIN LABS INC.
(Also in PDF format)

October 3, 2011
PALADIN LABS ADVISES THAT A CONDITION OF ITS OFFER FOR AFEXA LIFE SCIENCES CANNOT BE FULFILLED
(Also in PDF format)

September 26, 2011
PALADIN LABS CONFIRMS ENHANCED $0.81 PER SHARE OFFER TO ACQUIRE AFEXA LIFE SCIENCES
(Also in PDF format)

September 25, 2011
PALADIN LABS ANNOUNCES PROPOSED INCREASED OFFER TO ACQUIRE AFEXA LIFE SCIENCES FOR $0.81 PER SHARE
(Also in PDF format)

September 22, 2011
PALADIN LABS ANNOUNCES INTENTION TO ENHANCE OFFER FOR AFEXA LIFE SCIENCES
(Also in PDF format)

September 15, 2011
PALADIN LABS EXTENDS OFFER FOR AFEXA LIFE SCIENCES
(Also in PDF format)

September 6, 2011
PALADIN LABS INC. ISSUES UPDATE REGARDING JONATHAN ROSS GOODMAN
(Also in PDF format)

August 30, 2011
PALADIN CONSIDERS OPTIONS FOLLOWING ALTERNATE OFFER FOR AFEXA
(Also in PDF format)

August 30, 2011
PALADIN LABS ANNOUNCES DISTRIBUTION AGREEMENT FOR OTC WOMEN'S HEALTH DIAGNOSTICS
(Also in PDF format)

August 29, 2011
PALADIN'S PREMIUM OFFER REMAINS THE BEST CHOICE FOR AFEXA SHAREHOLDERS
(Also in PDF format)

August 18, 2011
PALADIN LABS INC. ISSUES ANNOUNCEMENT REGARDING JONATHAN ROSS GOODMAN
(Also in PDF format)

August 17, 2011
LABOPHARM INC. ENTERS INTO AN AGREEMENT TO BE ACQUIRED BY PALADIN LABS INC.
(Also in PDF format)

August 11, 2011
PALADIN REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS: ACHIEVES RECORD QUARTERLY REVENUES AND EBITDA
(Also in PDF format)

August 10, 2011
PALADIN LABS ANNOUNCES PREMIUM OFFER TO ACQUIRE AFEXA LIFE SCIENCES FOR $0.55 PER SHARE
(Also in PDF format)

August 4, 2011
NOTICE OF PALADIN LABS' SECOND QUARTER 2011 RESULTS CONFERENCE CALL
(Also in PDF format)

July 15, 2011
PALADIN LABS INC. ANNOUNCES PURCHASE OF SHARES OF AFEXA LIFE SCIENCES INC.
(Also in PDF format)

July 11, 2011
PALADIN LABS RAISES OVER $1.2 MILLION TO BENEFIT THE RIDE TO CONQUER CANCER
(Also in PDF format)

June 14, 2011
PALADIN LABS ANNOUNCES THE CANADIAN LAUNCH OF ABSTRAL(R)
(Also in PDF format)

June 8, 2011
SOMAXON AND PALADIN ANNOUNCE SILENOR(R) EX-US COLLABORATION
(Also in PDF format)

June 1, 2011
PALADIN LABS TO PRESENT AT THE JEFFERIES 2011 GLOBAL HEALTHCARE CONFERENCE IN NEW YORK
(Also in PDF format)

May 26, 2011
PALADIN LABS ANNOUNCES NORMAL COURSE ISSUER BID AND AUTOMATIC SHARE PURCHASE PLAN
(Also in PDF format)

May 25, 2011
PALADIN REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS-ACHIEVES RECORD QUARTERLY EBITDA

May 25, 2011
PALADIN LABS TO PRESENT AT THE BIOFINANCE CONFERENCE IN TORONTO
(Also in PDF format)

May 24, 2011
PALADIN LABS FILES NEW DRUG SUBMISSION FOR ORALAIR(TM)
(Also in PDF format)

May 19, 2011
PALADIN LABS TO PRESENT AT THE NATIONAL BANK FINANCIAL CONFERENCE IN MONTREAL
(Also in PDF format)

May 18, 2011
NOTICE OF PALADIN LABS' FIRST QUARTER 2011 RESULTS CONFERENCE CALL
(Also in PDF format)

May 17, 2011
PALADIN LABS ANNOUNCES REPAYMENT BY PROSTRAKAN OF SECURED DEBT
(Also in PDF format)

May 12, 2011
PALADIN AND ELAN SIGN AGREEMENT FOR NEW PAIN PRODUCT
(Also in PDF format)

May 10, 2011
PALADIN AND TAKEDA SIGN LICENSING AND DISTRIBUTION AGREEMENT FOR FOMEPIZOLE IN JAPAN
(Also in PDF format)

April 18, 2011
SEASONIQUE(TM) NOW AVAILABLE IN CANADA, THE NEXT GENERATION EXTENDED CYCLE PILL DESIGNED TO PROVIDE 4 MENSTRUAL PERIODS PER YEAR
(Also in PDF format)

March 29, 2011
PALADIN TO PRESENT AT THE 10TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE IN NEW YORK CITY
(Also in PDF format)

March 8, 2011
PALADIN TO PRESENT AT THE ROTH 23RD ANNUAL OC GROWTH STOCK CONFERENCE
(Also in PDF format)

February 24, 2011
PALADIN ANNOUNCES CLOSING OF $40.25 MILLION BOUGHT DEAL FINANCING
(Also in PDF format)

February 23, 2011
PALADIN TO PRESENT AT THE RBC CAPITAL MARKETS HEALTHCARE CONFERENCE IN NEW YORK CITY
(Also in PDF format)

February 22, 2011
PALADIN LABS OBTAINS CANADIAN APPROVAL FOR ABSTRAL(R)
(Also in PDF format)

February 22, 2011
PALADIN LABS ANNOUNCES PROPOSED CHANGE OF CONTROL OF PROSTRAKAN AND FURTHER INVESTMENT IN PHARMAPLAN
(Also in PDF format)

February 17, 2011
PALADIN REPORTS FIFTEENTH CONSECUTIVE YEAR OF RECORD REVENUES
(Also in PDF format)

February 10, 2011
NOTICE OF PALADIN LABS' FOURTH QUARTER 2010 RESULTS CONFERENCE CALL
(Also in PDF format)

February 3, 2011
PALADIN ENTERS INTO AGREEMENT FOR A $35.0 MILLION BOUGHT DEAL OF COMMON SHARES
(Also in PDF format)

February 1, 2011
PALADIN RECEIVES $1.0 MILLION RELATED TO AMENDMENT OF ISOTECHNIKA PARTNERSHIP
(Also in PDF format)

February 1, 2011
PALADIN ACQUIRES TEMPRA(R) FROM BRISTOL MYERS SQUIBB
(Also in PDF format)

January 27, 2011
PALADIN LABS OBTAINS CANADIAN APPROVAL FOR DIGIFAB(TM)
(Also in PDF format)

January 13, 2011
PALADIN LABS INC.: COMPLETION OF FINANCING AGREEMENT WITH PROSTRAKAN
(Also in PDF format)

HOME | SITE MAP | LEGAL DISCLAIMER